🔗 Share this article

Given that the US proceeds with unprecedented adjustments to its immunization recommendations, a particular individual appears unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who initially gained attention by casting doubt on Covid vaccinations throughout the global health crisis and has zeroed in on potential deaths following COVID-19 immunization in her recent time at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Agency leaders planned to reveal radical changes to the pediatric immunization program in December, aligning the US with Denmark’s national calendar, it is understood – a significant shift that would put the US at odds with a large portion of the international standard with insufficient data for public health gain. This reveal has been pushed back until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s CDER, the fifth person to lead the office this calendar year.

A New Direction at the Regulatory Body

This interim role could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

Høeg has repeatedly called for ending some pediatric shot schedules in the US so as to align more like the Danish model, a country with universal health coverage and a citizenry about the size of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – traditionally the domain of Prasad, head of the FDA’s vaccine center – rather than pharmaceutical oversight.

Questions Over Qualifications

The appointee has little discernible track record in pharmaceutical research, oversight or administrative roles, which has been customary for past leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for running the CDER, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in leading a large organization. She lacks background in drug approvals.”

Past commissioners of CBER would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, commented Janet Woodcock. “Clearly, she lacks the sort of resume that previous people who ran CBER have had.”

This division has an vast portfolio at the FDA, she pointed out.

“Many people just pays attention on the new drug program, but the generic drug division approves a multitude of generic medications. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one have to be managed,” Woodcock noted. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial leadership aspect to the role, which oversees more than 5,000 staff members. “It is a huge management job, if you perform it correctly,” the former official said.

Official Statement and Contentious Initiatives

Regarding questions about Dr. Høeg's credentials and whether this appointment indicates greater collaboration among FDA leaders on vaccines, a representative responded that the “questions stem from inaccurate presumptions”.

“Her experience aligns with the duties of her position,” the spokesperson stated, pointing to the time Dr. Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg inherits the agency head's controversial priority voucher program, a disputed rapid therapy clearance system that apparently worried her former heads. “By what process are these drugs being chosen for this voucher program? Who makes the calls?” Howard said. “There is a lot of lack of transparency going on at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards less stringent regulations of all drugs, with the exception of immunizations.”

Documented Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a clearer, if problematic, track record, some experts observe. She published a analysis using unconfirmed crowd-sourced reports to estimate the incidence of heart inflammation after COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Part of her “policy goals” for the current federal leadership featured altering guidelines for new vaccines and discontinuing “non-essential” vaccines, she stated post-election on a audio program. At the agency, Dr. Høeg has allegedly proposed excluding adolescent males from receiving COVID-19 vaccinations.

“She’s an thorough dogmatist who begins with her conclusions and tailors the evidence to accommodate the evidence in a very misleading, dishonest way,” Howard argued.

Consolidating Power and a “Revenge Tour”

Høeg aligned with other skeptics, {like|